Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
Open-label Phase IV trial of Letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( ER and PR)
Locally Advanced Breast Cancer
DRUG: Letrozole
Safety and tolerability of Letrozole, frequency and severity of the clinical adverse events
Open-label Phase IV trial of Letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( ER and PR)